Alessandra Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alessandra Costa has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Cavallin
Independent Statistician, 36020 Solagna, Italy
2 shared publications - Marco Rastrelli
Department of Surgical Oncology, Surgical Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
2 shared publications - Paolo Del Fiore
Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV—IRCCS, 35128 Padua, Italy
2 shared publications - Saveria Tropea
Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy
2 shared publications - Alessandro Parisi
UOC Radiotherapy, Istituto Oncologico Veneto, 35128 Padova, Italy
1 shared publication - Alessio Fabozzi
Medical Oncology, Second University of Naples, Naples, Italy
1 shared publication
Latest Publications
- 1 September 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (9) , 1520-1526
Myoepithelioma of the soft tissue: A systematic review of clinical reports
- 1 September 2019
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 45 (9) , 1520-1526
Myoepithelioma of the soft tissue: A systematic review of clinical reports
- Open Access
Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04–8.16) and disease-specific (HR 4.62, 95% CI 1.31–16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06–4.36) and recurrence-free (HR 3.08, 95% CI 1.44–6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival.
Open AccessPrognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients
Merkel Cell Carcinoma (MCC) is a rare but highly aggressive neuroendocrine neoplasm of the skin. This study aimed at describing characteristics, treatment, and prognosis of a series of consecutive cases of MCC patients, in order to contribute to the investigation of this rare malignancy and provide better patient care. This is a retrospective cohort study including all 90 patients diagnosed and/or treated for MCC between 1991 and 2018 at the Veneto Institute of Oncology in Padua (Italy). Patient and tumor characteristics, treatment, and immunohistochemical data were extracted from a prospectively collected local database. There were 68 primary (76%) and 22 non-primary (15 occult primary, three metastatic, four recurrence) tumors (24%). CK20 expression was associated with reduced overall (HR 2.92, 95% CI 1.04–8.16) and disease-specific (HR 4.62, 95% CI 1.31–16.28) survival. Immunomodulatory regimens for treatment of other comorbidities were associated with reduced disease-specific ((HR 2.15, 95% CI 1.06–4.36) and recurrence-free (HR 3.08, 95% CI 1.44–6.57) survival. Iatrogenic immunomodulation resulted as the main factor associated with impaired prognosis. Lack of CK20 expression was associated with better survival.